BRIEF-Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Biohaven Ltd.
Biohaven Ltd. BHVN | 0.00 |
March 19 (Reuters) - Biohaven Ltd BHVN.N:
BIOHAVEN'S PHASE 2 OBESITY STUDY WITH TALDEFGROBEP ALFA, A NOVEL MYOSTATIN-ACTIVIN PATHWAY INHIBITOR, COMPLETES ENROLLMENT
Source text: ID:nPn9VHmYna
Further company coverage: BHVN.N
